Immunometabolic regulation of human macrophages by the aryl hydrocarbon receptor
Introduction The aryl hydrocarbon receptor (AHR), initially characterized as a sensor of environmental toxicants, is now recognized as an important regulator of innate immunity and macrophage biology. Although AHR has been shown to influence macrophage polarization and the differentiation of human monocytes into monocyte-derived macrophages or dendritic cells, the molecular and metabolic mechanisms underlying AHR activation in primary human macrophages remain poorly characterized. This study aimed to investigate the effects of AHR activation on the functional, transcriptional, and metabolic profiles of human monocyte-derived macrophages. Methods Human monocyte-derived macrophages were treated with the xenobiotic AHR ligand 6-formylindolo[3,2-b]carbazole (FICZ). An integrative approach combining functional assays, transcriptomic profiling, and targeted metabolomics was used to characterize the effects of AHR activation. Results FICZ treatment increased cytosolic reactive oxygen species (ROS) production, mitochondrial mass, and basal respiration, while significantly reducing phagocytosis. Transcriptomic analyses revealed coordinated changes in pathways associated with immune regulation and cellular metabolism. Targeted metabolomics further identified metabolic alterations consistent with AHR-mediated cellular reprogramming. Discussion These findings provide an integrated characterization of the functional, transcriptional, and metabolic responses induced by AHR activation in human monocyte-derived macrophages. They offer new insights into the role of AHR in regulating macrophage immunometabolism and function.
Authors
- Silvia Marín (ORCID: https://orcid.org/0000-0003-0693-2207)
- Adrián Povo‐Retana (ORCID: https://orcid.org/0000-0002-3346-7155)
- Sergio Madurga (ORCID: https://orcid.org/0000-0002-8135-7057)
- Carmen Delgado (ORCID: https://orcid.org/0000-0002-0047-4674)
- Rodrigo Landauro‐Vera (ORCID: https://orcid.org/0000-0001-5364-6575)
- Carlota Alvarez‐Lucena (ORCID: https://orcid.org/0000-0002-7115-2111)
- Marta Cascante (ORCID: https://orcid.org/0000-0002-2062-4633)
- Lisardo Boscá
- Lucía Fernández-Frías (ORCID: https://orcid.org/0009-0001-2752-1696)
- Hengxin Huang
Institutions
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad Francisco de Vitoria (ES)
- Instituto de Salud Carlos III (ES)
- Barcelona Graduate School of Mathematics (ES)
- Instituto de Investigaciones Biomédicas Sols-Morreale (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Institut de Biomedicina de la Universitat de Barcelona (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fimmu.2026.1992380
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00